



SHIONOGI

U.S. Medical

[Read the full publication](#)

Real-World Effectiveness and Safety of Cefiderocol Treatment in Patients With Gram-Negative Bacterial Infections in Spain in the Early Access Program (EAP): Results of the PERSEUS Study


Summary of: Torre-Cisneros J, et al. *Eur J Clin Microbiol Infect Dis*. 2025;44(6):1375-1390.

SUMMARY

- **PERSEUS was a large real-world evidence study enrolling critically ill patients with carbapenem-resistant, Gram-negative pathogens (excluding *Acinetobacter* spp.)**
- The majority of pathogens were resistant to newer BL/BLI therapies
- **Cefiderocol treatment achieved a clinical cure rate of 80.5% and a Day 28 all-cause mortality rate of 21.5% in the overall population**
- Among patients with *P. aeruginosa* infections, clinical cure and Day 28 all-cause mortality rates were 84.5% and 17.2%, respectively
- **Adverse drug reactions were reported in 2.2% of study patients**


STUDY DESIGN

Retrospective, multicenter, observational, chart-review study




BASELINE CHARACTERISTICS

Critically ill population




Antibiotic treatment




Sites of infection


The most common **primary infection sites** were the **respiratory** and **urinary** tracts




Infection characteristics



Antibiotic resistance (N=261)




Resistance mechanisms^d (N=261)




CLINICAL OUTCOMES


Outcomes by species




Outcomes by infection site



Outcomes by antibiotic resistance




Risk factor analysis




Adverse Drug Reactions (ADR)

The safety population included all screened patients from the EAP in Spain (N=314)



CONCLUSIONS



STUDY LIMITATIONS

- Non-comparative, retrospective, observational study design; results should be considered as descriptive
- Small patient numbers in certain subgroups
- Cefiderocol use through the EAP in Spain may not precisely reflect its use in routine clinical practice in the United States
- Susceptibility information was based on reports in the medical charts without confirmation by a central laboratory
- Cefiderocol susceptibility testing was not routinely available in clinical microbiology laboratories at the time in Spain